Chimerix

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out in 2026. Company has high risk of loss despite expected $200 million in liquidity by the end of 2023.

Chimerix: Dangerous Road, Thesis Intact

Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"

Chimerix, Inc. (NASDAQ:CMRX ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Michelle Laspaluto - Vice President of Strategic Planning and Investor Relations Mike Andriole - President and CEO Josh Allen - Chief Technology Officer Allen Melemed - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Naureen Quibria - Capital One Joel Beatty - Baird Ed White - H.C. Wainwright Soumit Troy - Jones Trading Joseph Thome - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the Chimerix Second Quarter 2023 Earnings Conference Call.

Chimerix, Inc. (CMRX) Q2 2023 Earnings Call Transcript

Chimerix (CMRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.27 per share a year ago.

Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates

– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 –

Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update

Aptevo Therapeutics

Flexible Solutions

Glory Star New Media Group Holdings Ltd

Optex Systems Holdings Inc

X Financial - ADR

Yirendai Ltd. Sponsored

Millionaire-maker penny stocks, as you might guess from the title does not represent a universally accessible sector. While these ideas can possibly make you rich, they can just as easily make you poor.

7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes

DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 3, 2023 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2023, and to provide a business overview.

Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023

ACM Research

Rocky Brands

Tsakos Energy Navigation Limited

Vital Energy Inc

Zymeworks Inc

When dealing with the best small-cap stocks to buy, investors effectively absorb higher risk for the possibility of substantive rewards. Even better, these rewards can come in quickly, enabling those seeking a boost in their portfolio to make up for lost ground.

7 Small-Cap Stocks to Buy Before the Breakout

BioNTech SE

Celularity

Innoviva

Regeneron Pharmaceuticals

Voyager Therapeutics

Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of success to investors.

Why These 7 Stocks Are the Best Ways to Play Biotech Right Now

Mike Sherman to Transition to Chair of the Board of Directors Martha Demski to Assume Role of Lead Independent Director DURHAM, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Chimerix, Inc. (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the promotion of Mike Andriole, Chief Business Officer and Chief Financial Officer, to President and Chief Executive Officer of Chimerix and his appointment to the Board of Directors.

Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer

Today, we put the spotlight on Chimerix, Inc. for the first time in 12 months. The company is advancing its primary oncology candidate in development, has a potentially large market, and sells for less than net cash on its balance sheet. An updated investment analysis on Chimerix, Inc. follows in the paragraphs below.

Chimerix: A High-Risk 'Lottery Ticket'

HF Sinclair Corp

Sanmina-SCI

Peabody Energy

PCTEL

Typically, securities may be less appreciated by the market because they stink, which means several proposals for best undervalued growth stocks for June might not make the cut. At the same time, betting on the same ship as everyone else presents its own risks.

7 Deeply Undervalued Growth Stocks to Buy in June

DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 3:30 p.m. in New York City.

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

The biotechnology firm Chimerix has a high probability of success in its ongoing clinical trial in the treatment of pediatric brain tumors, according to analysts at Baird.  The firm initiated coverage of the North Carolina-based company with an Outperform rating and a $7 price target.

Chimerix's trial treating pediatric brain tumors has a 'relatively high' chance of success

Chimerix, Inc. (NASDAQ:CMRX ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President of Strategic Planning and Investor Relations Mike Sherman - President and Chief Executive Officer Allen Melemed - Chief Medical Officer Mike Andriole - Chief Financial and Business Officer Josh Allen - Chief Technology Officer Conference Call Participants Kevin Strang - Jefferies Naureen Quibria - Capital One Securities Ed White - H.C. Wainwright Troy Langford - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the Chimerix First Quarter 2023 Earnings Conference Call.

Chimerix, Inc. (CMRX) Q1 2023 Earnings Call Transcript

Chimerix (CMRX) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.28 per share a year ago.

Chimerix (CMRX) Reports Q1 Loss, Misses Revenue Estimates

– European Union Study Authorization for Phase 3 ACTION Received, Reiterate First Efficacy Data Expected Early 2025 –

Chimerix Reports First Quarter 2023 Financial Results and Provides Operational Update

DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, May 4, 2023 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2023, and to provide a business overview.

Chimerix to Report First Quarter 2023 Financial Results and Provide an Operational Update on May 4, 2023

Key Presentation Highlights Ability of ONC201 to Reverse Epigenetic Signature of H3 K27M Mutation in Glioma Patients

Chimerix Announces Presentation of Multiple Imipridone Datasets at American Association for Cancer Research Annual Meeting

AbCellera Biologics

Kiniksa Pharmaceuticals Ltd

Ocuphire Pharma

Point Biopharma Global

Vaccitech

Vir Biotechnology

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

Chimerix (CMRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Chimerix (CMRX) Loses -24.68% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Chimerix took quite a skid as it passed into the danger zone. Earnings for Q4, 2022 support an ongoing bull thesis for Chimerix.

Chimerix: Gaining Traction, Cash Runway To 2027

Beam Therapeutics

Dynavax Technologies

iTeos Therapeutics, Inc.

Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.

The Top 7 Growth Stocks in Biotech

Chimerix, Inc. (NASDAQ:CMRX ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President-Strategic Planning and Investor Relations Mike Sherman - President and Chief Executive Officer Josh Allen - Chief Technology Officer of Imipridones Mike Andriole - Chief Financial and Business Officer Allen Melemed - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Joseph Thome - TD Cowen Naureen Quibria - Capital One Securities Soumit Roy - Jones Research Operator Good morning, ladies and gentlemen, and welcome to the Chimerix Fourth Quarter and Year-End 2022 Earnings Conference Call. I would now like to introduce your host for today's call Michelle LaSpaluto, Vice President of Strategic Planning and Investor Relations at Chimerix.

Chimerix, Inc. (CMRX) Q4 2022 Earnings Call Transcript

- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study –

News for Chimerix Stock (CMRX)